182 related articles for article (PubMed ID: 28493520)
1. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity.
Meng F; Zhen S; Song B
APMIS; 2017 Aug; 125(8):743-751. PubMed ID: 28493520
[TBL] [Abstract][Full Text] [Related]
2. HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma.
Zhao L; Jin Y; Yang C; Li C
Clin Exp Immunol; 2020 Sep; 201(3):289-296. PubMed ID: 32474905
[TBL] [Abstract][Full Text] [Related]
3. CXCR5
Jin Y; Lang C; Tang J; Geng J; Song HK; Sun Z; Wang J
Int Immunopharmacol; 2017 Dec; 53():42-48. PubMed ID: 29032029
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-35 Suppresses Interleukin-9-Secreting CD4
Zhang Q; Yang L; Liu S; Zhang M; Jin Z
Front Immunol; 2021; 12():645835. PubMed ID: 34177894
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
[TBL] [Abstract][Full Text] [Related]
6. CD8
Nandi M; Pal S; Ghosh S; Chakraborty BC; Dey D; Baidya A; Shil A; Chattopadhyaya S; Banerjee S; Santra A; Chowdhury A; Datta S
Clin Sci (Lond); 2019 Sep; 133(17):1917-1934. PubMed ID: 31477625
[TBL] [Abstract][Full Text] [Related]
7. Overrepresentation of IL-10-Expressing B Cells Suppresses Cytotoxic CD4+ T Cell Activity in HBV-Induced Hepatocellular Carcinoma.
Xue H; Lin F; Tan H; Zhu ZQ; Zhang ZY; Zhao L
PLoS One; 2016; 11(5):e0154815. PubMed ID: 27136203
[TBL] [Abstract][Full Text] [Related]
8. Decrease of CD69 levels on TCR Vα7.2
Yong YK; Tan HY; Saeidi A; Rosmawati M; Atiya N; Ansari AW; Rajarajeswaran J; Vadivelu J; Velu V; Larsson M; Shankar EM
Innate Immun; 2017 Jul; 23(5):459-467. PubMed ID: 28606013
[TBL] [Abstract][Full Text] [Related]
9. Discrepant Clinical Significance of CD28
Shen XH; Xu P; Yu X; Song HF; Chen H; Zhang XG; Wu MY; Wang XF
Viral Immunol; 2018 Oct; 31(8):548-558. PubMed ID: 30117787
[TBL] [Abstract][Full Text] [Related]
10. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
11. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z
Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338
[TBL] [Abstract][Full Text] [Related]
13. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.
Cho HJ; Cheong JY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360777
[TBL] [Abstract][Full Text] [Related]
14. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
Cheng Y; Gunasegaran B; Singh HD; Dutertre CA; Loh CY; Lim JQ; Crawford JC; Lee HK; Zhang X; Lee B; Becht E; Lim WJ; Yeong J; Chan CY; Chung A; Goh BKP; Chow PKH; Chan JKY; Ginhoux F; Tai D; Chen J; Lim SG; Zhai W; Choo SP; Newell EW
Immunity; 2021 Aug; 54(8):1825-1840.e7. PubMed ID: 34270940
[TBL] [Abstract][Full Text] [Related]
15. High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection.
Gu S; Fu X; Ye G; Chen C; Li X; Zhong S; Tang L; Chen H; Jiang D; Hou J; Li Y
Front Immunol; 2021; 12():649197. PubMed ID: 34234772
[TBL] [Abstract][Full Text] [Related]
16. CXCR5
Jiang H; Li L; Han J; Sun Z; Rong Y; Jin Y
DNA Cell Biol; 2017 Apr; 36(4):321-327. PubMed ID: 28157399
[TBL] [Abstract][Full Text] [Related]
17. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma.
Sun R; Li J; Lin X; Yang Y; Liu B; Lan T; Xiao S; Deng A; Yin Z; Xu Y; Xiang Z; Wu B
Front Immunol; 2023; 14():1079495. PubMed ID: 37077908
[TBL] [Abstract][Full Text] [Related]
18. Immune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer.
Trehanpati N; Vyas AK
Scand J Immunol; 2017 Mar; 85(3):175-181. PubMed ID: 28109025
[TBL] [Abstract][Full Text] [Related]
19. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.
Chang JJ; Wightman F; Bartholomeusz A; Ayres A; Kent SJ; Sasadeusz J; Lewin SR
J Virol; 2005 Mar; 79(5):3038-51. PubMed ID: 15709024
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.
Sitia G; Aiolfi R; Di Lucia P; Mainetti M; Fiocchi A; Mingozzi F; Esposito A; Ruggeri ZM; Chisari FV; Iannacone M; Guidotti LG
Proc Natl Acad Sci U S A; 2012 Aug; 109(32):E2165-72. PubMed ID: 22753481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
